Tracking of glycated hemoglobin in the original cohort of the Framingham Heart Study

Journal of Clinical Epidemiology

Volumn 49, Issue 4, 1996, Pages 411-417

  Meigs, James B ^a   Nathan, David M ^a   Cupples, L Adrienne ^b   Wilson, Peter W F ^c   Singer, Daniel E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c Framingham Study   (United States)

Author keywords

Blood glucose; Epidemiological factors; HBA(1c); Hemoglobin A glycosylated; Longitudinal study

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; COHORT ANALYSIS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RELIABILITY; UNITED STATES;

EID: 0029875066     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/0895-4356(95)00513-7     Document Type: Article

References (36)

1. Bunn HF, Haney DN, Kamin S, Gabbey KH, Gallop PM. The biosynthesis of human hemoglobin A1: Slow glycosylation of hemoglobin in vivo. J Clin Invest 1976; 57:1652-1659.
2. Trivelli LA, Ranney HM, Lai HT. Hemoglobin components in patients with diabetes mellitus. N Engl J Med 1971; 284: 353-357.
3. Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984; 310: 341-346.
4. Svendsen P, Lauritzen T, Soegaard U, Nerup J. Glycosylated haemoglobin and steady-state mean blood glucose concentration in type 1 (insulin-dependent) diabetes. Diabetologia 1982; 23: 403-405.
5. Snger DE, Coley CM, Samet JH, Nathan DM. Tests of glycemia in diabetes mellitus: their use in establishing a diagnosis and in treatment. Ann Intern Med 1989; 100: 125-137.
6. Bunn HF, Evaluation of glycosylated hemoglobin in diabetic patients. Diabetes 1981; 30: 613-617.
7. Goldstein DE, Parker KM, England JD, England JE, Wiedmeyer H-M, Rawlings SS, Hess R, Littel RR, Simonds JF, Breyfogle RP. Clinical application of glycosylated hemoglobin measurements. Diabetes 1982; 31(Suppl. 3): 70-78.
8. Larsen ML, Horder M, Morgensen EF. Effect of long-term monitoring of glycosylated hemoglobin levels in insulin-dependent diabetes mellitus. N Engl J Med 1990; 323: 1021-1025.
9. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 1988; 260: 2864-2871.
10. Nathan DM, Singer DE, Godine JE, Harrington CH, Perlmutter LC. Retinopathy in older type II diabetics: Association with glucose control. Diabetes 1986; 35: 797-801.
11. Liu QZ, Pettit DJ, Hanson RL, Charles MA, Klein R, Bennett PH, Knowler WC. Glycated haemoglobin, plasma glucose and diabetic retinopathy: Cross-sectional and prospective analyses. Diabetologia 1993; 36: 428-432.
12. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
13. Ziegler D, Mayer P, Muhlen H, Gries FA. The natural history of somatosensory and autonomie nerve dysfunction in relation to glycaemic control during the first 5 years after diagnosis of type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1991; 34: 822-829.
14. 1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992; 41: 202-208.
15. 1c and sensitivity to various degrees of glucose intolerance. Ann Intern Med 1979; 91: 390-396.
16. Modan M, Meytes D, Rozeman P, Yosef SB, Sehayek E, Yosef NB, Lusky A, Halkin H. Significance of high HbA1 levels in normal glucose tolerance. Diabetes Care 1988; 11: 422-428.
17. Wilson PWF, Kannel WB, Anderson KM. Lipids, glucose intolerance and vascular disease: the Framingham Study. Monogr Atheroscler 1985; 13: 1-11.
18. Donahue RP, Abbott RD, Wilson PWF. Effect of diuretic use on the development of diabetes mellitus: The Framingham Study. In: Effects of Antihypertensive Treatment on Glucose Metabolism: International Symposium, Buhlerhohe, November, 1988. Thieme, New York, 1990, pp. 46-48.
19. World Health Organization. WHO Expert Committee on Diabetes Mellitus: Second Report (Tech. Rep. Ser., no. 646). World Health Organization, Geneva, 1980.
20. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-1057.
21. Forrest RD, Jackson CA, Yudkin JS. The glycohaemoglobin assay as a screening test for diabetes mellitus: The Islington Diabetes Survey. Diabetic Med 1987; 4: 254-259.
22. Nathan DM. Labile glycosylated hemoglobin contributes to hemoglobin A1 as measured by liquid chromatography or electrophoresis. Clin Chem 1981; 27: 1261-1263.
23. McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipid lipoprotein fractions. Clin Chim Acta 1987; 166: 1-8.
24. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-magnesium precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem 1982; 28: 1379-1382.
25. Cupples L, D'Agostino R. Section 34: Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements: Framingham Heart Study, 30-year followup. In: The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease (Kannel W, Wolf P, Garrison R, eds.). U.S. Department of Commerce, Washington, D.C., 1988.
26. SAS/STAT User's Guide, version 6, 4th Ed. SAS Institute, Inc., Cary, North Carolina, 1989.
27. Shrout PE, Fleiss JL. Intraclass correlations: Uses in assessing rater reliability. Psych Bull 1979; 86: 420-428.
28. Belanger A, Cupples L, D'Agostino R. Section 36: Means at each examination and inter-examination consistency of specified characteristics: Framingham Heart Study, 30-year follow-up. In: The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease (Kannel W, Wolf P, Garrison R, eds.). U.S. Department of Health and Human Services, Washington, D.C., 1988.
29. Criqui MH, Frankville DD, Barrett-Connor E, Klauber MR, Holdbrook MJ, Turner JD. Change and correlates of change in high and low density lipoprotein cholesterol after six years: A prospective study. Am J Epidemiol 1983; 118: 52-59.
30. Little RR, England JD, Weidmeyer HM, Madsen RW, Pettitt DJ, Knowler WC, Goldstein DE. Glycated haemoglobin predicts progression to diabetes mellitus in Pima Indians with impaired glucose tolerance. Diabetologia 1994; 37: 252-256.
31. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: Does the clock for coronary heart disease start ticking before the onset of diabetes? JAMA 1990; 263: 2893-2898.
32. Harris MI, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes 1987; 36: 523-534.
33. Wilson PWF, Anderson KM, Kannel WB. Epidemiology of diabetes mellitus in the elderly: The Framingham Study. Am J Med 1986; 80(Suppl. 5A): 3-9.
34. Knowler WC, Pettit DJ, Savage PJ, Bennett PH. Diabetes incidence in Pima Indians: Contributions of obesity and parental diabetes. Am J Epidemiol 1981; 113: 144-156.
35. Barrett-Connor E, Criqui MH, Witztum JL, Phillipi T, Zettner A. Population-based study of glycosylated hemoglobin, lipids, and lipoproteins in nondiabetic adults. Arteriosclerosis 1987; 7: 66-70.
36. Simon D, Senan C, Garnier P, Saint-Paul M, Papoz L. Epidemiological features of glycated haemoglobin Alc-distribution in a healthy population. Diabetologia 1989; 32: 864-869.